secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001493152-26-007204
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma prelim FY2025 net loss widens to ~$11-12M; G&A up 3.6x on investor ads
--------------------------------------------------------------------------------

- Preliminary FY2025 net loss expected between $10.9M and $12.1M vs $9.1M in FY2024; revenue remains zero.
- G&A expense surged to $5.2-5.8M from $1.4M, driven by $3.6M in investor relations advertising costs.
- Working capital turns negative to deficit of $0.7-0.8M from positive $0.7M; cash used for Molecule.ai acquisition and trial wind-down.
- Intangible assets of $9.8M from Molecule.ai acquisition; contingent consideration of $2.0M and consideration payable of $4.4M.
- All convertible notes converted to stock; company needs additional financing to continue as going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226007204/0001493152-26-007204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315226007204/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer